Rapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market
BD AccelerateSM Program Designed to Bring Pharmaceutical Customers' Drugs to Market Faster
FRANKLIN LAKES, N.J., Nov. 19, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that the BD AccelerateSM program now offers a solution for the biopharmaceutical injectable drug market with the BD Neopak™ Glass Prefillable Syringe system. This make-to-stock program is designed to facilitate expedited delivery, within two weeks, of fully-validated BD syringe systems and associated quality systems documentation to pharmaceutical customers.
Launched in 2011, the program was designed to offer pharmaceutical customers faster access to fully-validated syringe systems that are optimized for biologics, vaccines and other parenteral medicines. Based on BD's high-speed manufacturing capabilities, the BD AccelerateSM program allows the company to produce and store large quantities of fully-validated syringe components. This program represents a significant reduction in lead time versus traditional processes and provides customers with the advantage to initiate testing earlier in the drug development process.
"By offering faster access to a syringe system that is specifically engineered for the delivery of biopharmaceutical drugs, BD is positioned to provide an important advantage to companies developing these products to address a wide range of unmet healthcare needs," said Eric Borin, Vice President and General Manager – Americas, BD Medical – Pharmaceutical Systems. "The availability of the BD Neopak™ Glass Prefillable Syringe system through the BD AccelerateSM program demonstrates BD's understanding of its pharmaceutical partners' current challenges when bringing drugs to market for patients."
Building on more than 100 years of industry expertise, BD selected products suited to specific market needs with attributes to reduce regulatory and drug compatibility risks intended to enable pharmaceutical companies to expedite drug products through the development stages. The current syringe systems offered through the program include BD Neopak™ Glass Prefillable Syringes, BD Hypak™ Glass Prefillable Syringes and BD Hypak™ Glass Prefillable Syringes for Biotech. As of January 2013, more than 40 BD pharmaceutical partners have participated in the BD AccelerateSM program.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD (Becton, Dickinson and Company)
Released November 19, 2013